PCOS and Hormones: Root Causes, Testing & Evidence-Based Treatment

The Insulin Resistance–PCOS Connection

Insulin resistance is the primary driver of PCOS in 70–80% of cases — not a comorbidity, but the upstream cause. Understanding this mechanism is essential for both diagnosis and treatment.

How hyperinsulinemia drives androgen excess: Insulin and IGF-1 (insulin-like growth factor 1) stimulate ovarian theca cells to produce androgens — specifically testosterone and androstenedione. This effect is dose-dependent: the more chronically elevated insulin is, the more androgen the ovaries produce. In parallel, elevated insulin suppresses hepatic SHBG (sex hormone-binding globulin) production, which would normally bind and neutralize free testosterone. The result: both total and free testosterone rise, driving the acne, hirsutism, and hair loss that characterize PCOS.

HOMA-IR threshold for PCOS: A 2020 meta-analysis in Frontiers in Endocrinology found that a HOMA-IR cutoff of 2.0 identifies insulin resistance in PCOS patients with 80% sensitivity and 73% specificity. HOMA-IR above 2.0 strongly predicts androgen excess severity and should prompt aggressive metabolic intervention. Women with lean PCOS (BMI <25) can still have HOMA-IR above 2.0 — this is why waist circumference and fasting insulin testing matter more than BMI alone.

Why metformin + inositol work: Metformin inhibits hepatic glucose production and reduces insulin levels, which directly lowers LH-stimulated androgen production in the ovaries. Myo-inositol (a naturally occurring insulin sensitizer) acts as a second messenger in the insulin signaling cascade — it is deficient in the follicular fluid and ovarian tissue of women with PCOS. Supplementation at 4g myo-inositol + 100 mg D-chiro-inositol (40:1 ratio) has been shown in RCTs to reduce fasting insulin by 20–30%, lower testosterone by 15–25%, and restore ovulation in approximately 65% of patients (Nordio et al., European Review for Medical and Pharmacological Sciences, 2012). Combining inositol with metformin further amplifies insulin sensitization and may be more effective than either alone (Artini et al., Gynecological Endocrinology, 2013). For more on the insulin–PCOS cycle, see our guide on supplements for insulin resistance.

The Hormonal Profile of PCOS

PCOS Treatment: Addressing Root Causes

Insulin sensitization (first-line):

• Dietary modification: Reduce refined carbohydrates and glycemic load. Mediterranean and low-GI diets improve insulin sensitivity and reduce androgens in RCTs. Target 25-30g fiber daily.
• Metformin (1,500-2,000 mg/day): Reduces insulin and androgens, may restore ovulation in 30-50% of women (Cochrane Review).
• Inositol: Myo-inositol (4g/day) + D-chiro-inositol (100 mg/day) in a 40:1 ratio improves insulin sensitivity, reduces androgens, and restores ovulation with fewer side effects than metformin. Multiple RCTs support its use (Endocrine Society review, 2017).
• Exercise: 150 min/week moderate activity improves insulin sensitivity independent of weight loss.

Anti-androgen strategies:

• Spironolactone (50-200 mg/day) — blocks androgen receptors; effective for hirsutism and acne (4-6 months for results)
• Combined oral contraceptives — increase SHBG, reduce free testosterone
• Weight loss — 5-10% body weight reduction can decrease androgens by 20-30% and restore ovulation

PCOS and Long-Term Health Risks

PCOS is not just a reproductive condition — it carries significant metabolic and cardiovascular implications:

• Type 2 diabetes: Women with PCOS have a 4-8x increased risk. 40% will develop pre-diabetes or diabetes by age 40 (JCEM, 2012).
• Cardiovascular disease: Increased risk of hypertension, dyslipidemia, and subclinical atherosclerosis.
• Endometrial cancer: Chronic anovulation leads to unopposed estrogen stimulation of the endometrium, increasing cancer risk 2-6x.
• Mental health: 40% prevalence of anxiety, 30% depression — partly hormonal, partly related to symptom burden.
• Sleep apnea: 5-30x increased risk, driven by androgen excess and obesity.

Annual screening for glucose intolerance (OGTT preferred over HbA1c in PCOS), lipid panel, blood pressure, and endometrial thickness (if periods absent >3 months) is recommended by the Endocrine Society.